Maryland’s Prescription Drug Affordability Board will issue revised proposed regulations meant to guide the panel’s work on making some medications more affordable, following criticisms and feedback during a public comment period, according to Andrew York, the board’s executive director.
During a Monday virtual meeting, York said a new draft will be released after a dozen “really great” written comments from various members of the medical community were submitted to the board, including concerns that the original proposed rules were too vague and didn’t seek enough input from the public.
“I can say some key themes that we saw were that many commenters would like to see some additional guidance and specificity in the regulations whenever we can provide it,” he said.
“Also, there was a lot of feedback just ensuring that we have high quality data that we’re using and considering,” he said, “and a lot of requests for opportunities for public feedback and input throughout the process for identifying drugs for eligibility and selection of the drugs and the actual cost review itself.”
